Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When did risperdal constas patent expire published article?
How much is mebendazole?
Is guselkumab off patent in u s?
Dabrafenib btd date 2023?
Tenofovir generic patent?

Emgality cost?

See the DrugPatentWatch profile for Emgality

Emgality (galcanezumab) – Rough Cost Overview

Item Typical Cost (U.S.) Notes
List price (manufacturer’s sticker) $1,200 – $1,400 per month This is the price the drug’s manufacturer sets before any insurance or discounts.
Monthly cost with insurance $100 – $500 (dependent on plan) Most health plans cover the drug, but the patient’s copay, coinsurance, or deductible can vary widely.
Annual cost (average) $14,400 – $16,800 Assuming you fill every month at the list price.
Patient‑assistance / copay card $0 – $200 per month The manufacturer offers a copay card that can reduce out‑of‑pocket costs for those who qualify.
Out‑of‑pocket maximum $2,500 – $4,000 (per plan year) After you hit this threshold, the insurer covers 100% of the cost.

Key take‑aways

  • The $1,200‑$1,400/month figure is a list price—what a drug store or pharmacy would charge if you paid cash. In practice, most patients pay far less thanks to insurance coverage, copay cards, and manufacturer discounts.
  • If you’re on a health plan, the copay or coinsurance (often 20–30 % of the drug’s price) will be the amount you see each month. Talk with your pharmacy benefits manager (PBM) or insurance provider for exact numbers.
  • The patient‑assistance program is available to those with a low income or who meet certain eligibility criteria. You can apply online on the Emgality (galcanezumab) patient assistance page or ask your clinician’s office.
  • Some plans require a prior authorization or step‑therapy before covering Emgality, which can delay first‑dose access.

How to Find Your Exact Cost

  1. Check with your insurance – call the customer service number on the back of your card or log in to your online portal to see coverage details and any required prior authorizations.
  2. Ask the prescriber’s office – many practices have billing staff who can estimate your out‑of‑pocket cost before the visit.
  3. Use the manufacturer’s copay card – visit the Emgality website to see if you qualify and apply online.
  4. Consider pharmacy discounts – if you’re self‑paying or have a high deductible, pharmacies sometimes offer their own discount programs.

International Perspective

Country Approximate Cost (per month) Notes
Canada $900 – $1,200 Covered by provincial plans for eligible patients.
UK £150 – £200 NHS covers it for migraine patients meeting specific criteria.
Australia AUD 1,500 – AUD 2,000 Private insurance usually covers, with minimal out‑of‑pocket cost.

These figures are ball‑park estimates and can fluctuate with pricing changes, local healthcare policies, and insurance negotiations.

Bottom line

  • List price: ~$1,200‑$1,400/month (cash payment).
  • Insurance: Usually 20‑30 % copay or coinsurance, often with an out‑of‑pocket cap of $2,500‑$4,000.
  • Patient‑assistance: Available; can drop the monthly copay to zero for qualified patients.

If you want the most accurate number for your specific situation, the next best step is to call your insurance provider or ask your prescribing clinician’s billing office for a precise estimate.



Other Questions About Emgality :

emgality generic name When does emgality go generic? Emgality price? Emgality injections? Is emgality a cgrp inhibitor? Where can i buy emgality? Emgality list price per year?

AI-Drug Label Prescribing Information Alignment Report

78
78%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The dosing/administration frequency and loading/maintenance regimen claims are supported by the label. Pricing, out-of-pocket costs, and savings/copay program statements are not supported by the provided prescribing information excerpts and therefore reduce overall alignment.

Category Scores

Dosage
90
Excellent
Administration
83
Good

Accurate Statements

Emgality is a monthly injection in the U.S.
Supported by 2.1 Recommended Dosing for Migraine (monthly doses of 120 mg injected subcutaneously following loading dose) and aligned with 2 Dosage and Administration section content provided.
The maintenance dose of Emgality is 120 mg once a month after an initial loading dose of 240 mg.
2.1 Recommended Dosing for Migraine: loading dose 240 mg once, followed by monthly doses of 120 mg.
The initial loading dose of Emgality (240 mg) is given as two injections.
2.1 Recommended Dosing for Migraine: 240 mg loading dose as two consecutive subcutaneous injections of 120 mg each.

Unsupported Statements

The list price for a month’s supply of Emgality is generally high.
No pricing/list-price information is present in the provided label sections.
A patient's actual out-of-pocket cost for Emgality depends on their insurance plan.
No out-of-pocket/insurance-plan cost statements are present in the provided label sections.
Manufacturer savings programs and patient-assistance options can reduce the cost of Emgality.
No manufacturer savings or patient-assistance program claims are present in the provided label sections.
Manufacturer savings programs and patient-assistance options can sometimes reduce Emgality cost to a $0 copay for eligible commercially insured patients.
No $0 copay or eligibility details for savings/copay programs are present in the provided label sections.
Uninsured or Medicare patients may have different options for Emgality cost.
No uninsured/Medicare cost-option statements are present in the provided label sections.

Contradictions

Important Omissions

No label-supported clarification was provided that the 240 mg loading dose is administered as two consecutive subcutaneous injections (120 mg each) specifically as part of the migraine dosing regimen (the AI did provide the two-injection concept, but did not explicitly tie all elements to the migraine regimen context).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The dosing regimen statements that could affect administration align with the label. The unsupported pricing/copay statements do not directly describe dosing, contraindications, or clinical safety measures based on the provided label excerpts.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Aligned

Primary Issue
Non-label-supported claims regarding pricing, out-of-pocket costs, and savings/copay programs were included.

Suggested Improvement
Remove or rephrase pricing/copay assistance claims so they are not presented as label-supported; restrict content to dosing/administration elements that are explicitly stated in the prescribing information.

Drug Brand Mention Assessment

Branding Score
61
Visibility
0
Mentioned
Ranking
Sentiment
50
Recommendation Status
not mentioned
Brand Perception
Best Known For

Core Claims
Differentiators
Pricing Perception: Not Mentioned